AstraZeneca India names Dr Sanjeev Panchal as Country President, MD
Sanjeev is currently the Country President for AstraZeneca Malaysia.
Bangalore: Biopharmaceutical company, AstraZeneca Pharma India Ltd has announced a change in its leadership with the appointment of Dr. Sanjeev Panchal as Country President & Managing Director, AstraZeneca Pharma India Ltd with effect from 1st January 2023.
Sanjeev has been with AstraZeneca for 19 years and began his career in India back in 2003 as a Brand Associate. Over time, he progressed through several positions in India, Indonesia, Asia Pacific, and International region, based in Singapore and the UK.
Sanjeev is currently the Country President for AstraZeneca Malaysia. He played a critical role in supporting the government in combating the pandemic through AstraZeneca's Covid-19 vaccine and long-acting monoclonal antibodies, as well as leading the Corporate Affairs strategy and sustainability initiatives.
Commenting on his appointment, Dr Sanjeev Panchal said, "AstraZeneca's bold ambition is to be pioneers in science and transform patient outcomes by delivering a robust pipeline of new medicines and leading in sustainability. Expansion, innovation, and patient-centric partnership are at the heart of how we make health happen, supported by the diversity of our organisation and driven by our shared goal. I am delighted to return to India and take on the journey that Gagandeep Singh has established for the country, and I am really looking forward to collaborating with the team as we continue to push the boundaries of science to make health happen for people, society and planet".
Sanjeev is a Science graduate (BSc) with Post Graduation and Doctorate in Business Administration (PhD).
Gagandeep Singh the current Country President led the entity in India from a primary care company to a specialty care powerhouse. Expressing his delight in on-boarding Sanjeev, he said, "I would like to congratulate the entire India team for achieving great feat in the past 5 years despite the pandemic. With strong consistent growth across disease areas, we are today poised to achieve leadership in existing portfolio and to explore more areas to be able to extend benefits to more and more patients. I am very happy to see my fellow colleague and friend Sanjeev coming into this role and wish him all the best to capitalise on the opportunity ahead of us."
Sanjeev will be assuming the new role starting January 2023 and will be taking forward the commitment of the organisation in the country.
Read also: AstraZeneca gets CDSCO Panel nod to market anticancer drug Acalabrutinib
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.